IRIS
BUTTITTA, Fiamma
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.827
NA - Nord America 2.801
AS - Asia 1.101
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 6
OC - Oceania 5
AF - Africa 1
Totale 6.748
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.790
CN - Cina 582
UA - Ucraina 533
IE - Irlanda 477
SE - Svezia 379
IT - Italia 377
GB - Regno Unito 367
TR - Turchia 310
FR - Francia 276
DE - Germania 168
FI - Finlandia 95
IN - India 93
RU - Federazione Russa 92
SG - Singapore 80
CZ - Repubblica Ceca 22
BE - Belgio 20
CA - Canada 10
IL - Israele 8
VN - Vietnam 8
EU - Europa 7
NL - Olanda 7
HK - Hong Kong 6
JP - Giappone 6
CL - Cile 3
NZ - Nuova Zelanda 3
PK - Pakistan 3
PL - Polonia 3
TW - Taiwan 3
AU - Australia 2
CH - Svizzera 2
CO - Colombia 2
DK - Danimarca 2
IR - Iran 2
NO - Norvegia 2
RO - Romania 2
BR - Brasile 1
GR - Grecia 1
LU - Lussemburgo 1
MX - Messico 1
RS - Serbia 1
SC - Seychelles 1
Totale 6.748
Salva come PNG Salva come JPEG
Città #
Chandler 653
Jacksonville 610
Dublin 468
Southend 264
Princeton 231
Izmir 188
Nanjing 186
Beijing 116
Ashburn 111
Cambridge 101
Dearborn 101
Wilmington 90
Altamura 71
Boardman 70
Ann Arbor 67
Chieti 60
Nanchang 57
Singapore 52
Shenyang 47
New York 42
Tianjin 29
Hebei 26
Woodbridge 26
Hangzhou 24
Kunming 23
Grevenbroich 21
Washington 21
Augusta 16
Brussels 16
Jiaxing 15
Pescara 15
Jinan 14
Norwalk 14
Rome 14
San Mateo 14
Brno 13
Los Angeles 13
Milan 13
Collecorvino 12
Ningbo 12
Orange 11
Munich 9
Changsha 8
Dong Ket 8
Latina 8
Montesilvano 8
Toronto 8
Auburn Hills 7
Olomouc 7
Falls Church 6
Helsinki 6
Lanzhou 6
Tappahannock 6
Varallo 6
Fairfield 5
Leawood 5
Hanover 4
Hong Kong 4
Houston 4
Verona 4
Zhengzhou 4
Andover 3
Cavacurta 3
Civitanova Marche 3
Gloucester 3
Seattle 3
Taizhou 3
Valduggia 3
Bari 2
Changchun 2
Clearwater 2
Council Bluffs 2
Eden Prairie 2
Edinburgh 2
Florence 2
Gent 2
Hyderabad 2
Islamabad 2
Karasawa 2
Klausen 2
Macerata 2
Montréal 2
New Delhi 2
Oslo 2
Pistoia 2
Saint Louis 2
San Vito Chietino 2
Santa Marta 2
Selvazzano Dentro 2
Tokyo 2
Torino 2
Turin 2
Waanrode 2
Walnut 2
Anagni 1
Ancona 1
Apo 1
Aquila 1
Aradeo 1
Ardabil 1
Totale 4.149
Salva come PNG Salva come JPEG
Nome #
Validation of a new algorithm for a quick and easy RT-PCR-based ALK test in a large series of lung adenocarcinomas: Comparison with FISH, immunohistochemistry and next generation sequencing assays 115
ALK protein analysis by IHC staining after recent regulatory changes: A comparison of two widely used approaches, revision of the literature, and a new testing algorithm 106
Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing. 97
Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors 95
A unique microRNA signature associated with ischemic stroke in humans 92
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in human. 90
Why anti-PD1/PDL1 therapy is so effective? Another piece in the puzzle 88
Down regulation of high in normal-1 (HIN-1) is a frequent event in stage I non-small cell lung cancer and correlates with poor clinical outcome. 87
A unique microRNA signature associated with plaque instability in humans. 86
ATP-binding cassette transporter A1 (ABCA1) overexpression in hypercholesterolemic plaques: a potential molecular explanation 85
Optimizing Single Agent Panitumumab Therapy in Pre-Treated Advanced Colorectal Cancer 85
ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme 85
Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: A case report 84
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: Toward a real-time liquid biopsy for treatment 83
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. 81
ROS1 Gene Fusion in Advanced Lung Cancer in Women: A Systematic Analysis, Review of the Literature, and Diagnostic Algorithm 80
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 79
Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. 78
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma. 78
Overexpression of ABCA1 in human plaques exposed to hypercholesterolemia: the role of microRNA modulation 78
Int6 expression can predict survival in early-stage non-small cell lung cancer patients. 78
Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control 77
Assessing EGFR mutations. 76
AKT1(E17K) in human solid tumours 76
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis. 76
PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. 74
Gene mutations in small-cell lung cancer (SCLC): Results of a panel of 6 genes in a cohort of Italian patients 74
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation 73
Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. 73
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. 72
Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. 72
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. 71
Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients 71
The chromosomal location of the mouse mammary tumor gene Int6 and related pseudogenes in the mouse genome. 69
Survivin gene expression in early-stage non-small cell lung cancer. 68
Correspondence - In Reply - Limitations of Single-Strand Conformation Polymorphism Analysis As a High-Throughput Method for the Detection of EGFR Mutations in the Clinical Setting 68
Survival prediction of stage I lung adenocarcinomas by expression of 10 genes. 68
Complex Mutations & Subpopulations of Deletions at Exon 19 of EGFR in NSCLC Revealed by Next Generation Sequencing: Potential Clinical Implications. 68
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives 68
ABCA-1 expression is reduced in atherosclerotic plaques from hypertensive patients: a new potential link between hypertension and atherosclerosis 67
p53 alterations in non-small cell lung cancer correlate with metastatic involvement of hilar and mediastinal lymph nodes 66
Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. 66
Enriched SSCP: a highly sensitive method for the detection of unknown mutations. Application to the molecular diagnosis of lung cancer in sputum samples. 66
Mutational profile of GNAQQ209 in human tumors. 66
Reduction of atherothrombotic burden before stent deployment in non-ST elevation acute coronary syndromes: Reduction of myocardial necrosis achieved with nose-dive manual thrombus aspiration (REMNANT) trial. A volumetric intravascular ultrasound study 66
Host genetic background effect on the frequency of mouse mammary tumor virus-induced rearrangements of the int-1 and int-2 loci in mouse mammary tumors. 65
Detection of gene mutations on cytological specimens: clinical implications 65
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. 65
microRNAs Derived from Circulating Exosomes as Noninvasive Biomarkers for Screening and Diagnosing Lung Cancer. 64
Bronchioloalveolar carcinoma: K-ras mutations are constant events in the mucinous subtype 63
Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up 63
mdm2 gene alterations and mdm2 protein expression in breast carcinomas 63
Lung tumours from non-smoking subjects: A p53-related genetic instability in a subset of cases. 62
mRNA markers of breast cancer nodal metastases: comparison between mammaglobin and carcinoembryonic antigen in 248 patients. 62
Hypertension is a determinant of ABCA1 expression in atherosclerotic plaques from hypercholesterolemic patients 62
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. 62
The chromosome location of the human homolog of the mouse mammary tumor-associated gene INT6 and its status in human breast carcinomas. 61
Telomerase Activity as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer 61
Stabilita’ del dna in campioni citologici conservati in fase liquida 61
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors. 61
null 61
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies 61
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy 61
IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. 60
Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. 60
Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. 59
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 59
Early prediction of resistance to tyrosine kinase inhibitors by plasma monitoring of EGFR mutations in NSCLC: A new algorithm for patient selection and personalized treatment 58
MDM4 (MDMX) localizes at the mitochondria and facilitates the p53-mediated intrinsic-apoptotic pathway. 57
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy. 57
Int-6, a highly conserved, widely expressed gene, is mutated by mouse mammary tumor virus in mammary preneoplasia. 56
Genetic analysis of lung tumors of non-smoking subject: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus 55
Evaluation of FHIT gene alterations in ovarian cancer 55
Hypertension modulates miR-145 expression in human atherosclerotic plaques 55
Quantification of EGFR Mutations in Plasma of NSCLC Patients: An Early Predictor of Clinical Response to Tyrosine Kinase Inhibitor 55
p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. 53
Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients 53
Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. 53
Predictive markers in lung cancer: A few hints for the practicing pathologist 53
Telomerase activity as a prognostic indicator in Stage I Non- Small Cell Lung Cancer -Gruppo Italiano di Patologia Molecolare II Riunione Scientifica. Pisa 20-22 Giugno99 52
Adjuvant osimertinib treatment in patients with early stage NSCLC (IB-IIIA): pathological pathway adaptations 52
Prostatic cancer: molecular bases. 51
Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: An update from clinical practice 51
Multiple regions of chromosome 6q affected by loss of heterozygosity in primary human breast carcinomas. 50
p53 mutations and histologic type of invasive breast carcinoma. A polymerase chain reaction-single-strand conformation polymorphism and immunohistochemical analysis. 50
p53 mutations and histological type of invasive breast carcinoma. 49
Reduced expression of INT-6/eIF3-p48 in human tumors. 49
p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. 48
Nucleotide and deduced amino acid sequences of tumor gene INT6. 48
Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression. 47
Association between cigarette smoking and FHIT gene alterations in lung cancer. 47
p53 status is neither a predictive nor a prognostic variable in patients with advanced ovarian cancer treated with a paclitaxel-based regimen. 47
Cell cycle-related gene abnormalities and product expression in esophageal carcinoma. 46
Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. 46
Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. 46
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study 42
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. 42
An innovative diagnostic strategy for the detection of rare molecular targets to select cancer patients for tumor-agnostic treatments 41
P53 and C-erbb-2 alterations in in-situ and invasive ductal breast carcinomas - a genetic and immunohistochemical analysis. 38
Microsatellite alterations and p53, TGFbetaRII, IGFIIR and BAX mutations in sporadic non-small-cell lung cancer. 36
Totale 6.520
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.401
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.401
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.366 431 98 18 46 87 80 149 121 30 139 156 11
2020/2021663 114 8 119 5 53 132 17 3 77 93 6 36
2021/2022603 18 7 8 131 31 23 13 38 50 33 84 167
2022/20231.709 144 216 70 212 193 345 96 105 233 12 46 37
2023/2024762 68 24 44 23 50 229 153 33 4 27 2 105
2024/2025101 101 0 0 0 0 0 0 0 0 0 0 0
Totale 6.979